Tumorigenic activity and therapeutic inhibition of Rheb GTPase

Mavrakis, K. J., Zhu, H., Silva, R. L., Mills, J. R., Teruya-Feldstein, J., Lowe, S. W., Tam, W., Pelletier, J., Wendel, H. G. (August 2008) Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev, 22 (16). pp. 2178-88.

[thumbnail of Paper]
PDF (Paper)
Lowe Genes Dev 2008.pdf - Published Version

Download (623kB) | Preview
URL: http://www.ncbi.nlm.nih.gov/pubmed/18708578
DOI: 10.1101/gad.1690808


The AKT-mTOR pathway harbors several known and putative oncogenes and tumor suppressors. In a phenotypic screen for lymphomagenesis, we tested candidate genes acting upstream of and downstream from mTOR in vivo. We find that Rheb, a proximal activator of mTORC1, can produce rapid development of aggressive and drug-resistant lymphomas. Rheb causes mTORC1-dependent effects on apoptosis, senescence, and treatment responses that resemble those of Akt. Moreover, Rheb activity toward mTORC1 requires farnesylation and is readily blocked by a pharmacological inhibitor of farnesyltransferase (FTI). In Pten-deficient tumor cells, inhibition of Rheb by FTI is responsible for the drug's anti-tumor effects, such that a farnesylation-independent mutant of Rheb renders these tumors resistant to FTI therapy. Notably, RHEB is highly expressed in some human lymphomas, resulting in mTORC1 activation and increased sensitivity to rapamycin and FTI. Downstream from mTOR, we examined translation initiation factors that have been implicated in transformation in vitro. Of these, only eIF4E was able to enhance lymphomagenesis in vivo. In summary, the Rheb GTPase is an oncogenic activity upstream of mTORC1 and eIF4E and a direct therapeutic target of farnesyltransferase inhibitors in cancer.

Item Type: Paper
Uncontrolled Keywords: Animals Antibiotics, Antineoplastic/pharmacology Blotting, Western Cell Aging Cell Transformation, Neoplastic/*pathology Cells, Cultured Doxorubicin/pharmacology Eukaryotic Initiation Factor-4E/*metabolism Farnesyltranstransferase/*antagonists & inhibitors/metabolism Female Fibroblasts/cytology/metabolism Gene Dosage Humans Immunophenotyping Immunosuppressive Agents/pharmacology Lymphoma/metabolism/*pathology Mice Mice, Inbred C57BL Mice, Knockout Monomeric GTP-Binding Proteins/*antagonists & inhibitors/metabolism Neuropeptides/*antagonists & inhibitors/metabolism PTEN Phosphohydrolase/physiology Phosphorylation Piperidines/pharmacology Proto-Oncogene Proteins c-akt/metabolism Proto-Oncogene Proteins c-myc/physiology Pyridines/pharmacology RNA, Messenger/genetics/metabolism Reverse Transcriptase Polymerase Chain Reaction Signal Transduction Sirolimus/pharmacology Transcription Factors/*metabolism Tumor Suppressor Protein p53/physiology
Subjects: diseases & disorders > cancer
diseases & disorders
bioinformatics > genomics and proteomics > genetics & nucleic acid processing
bioinformatics > genomics and proteomics
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification
CSHL Authors:
Communities: CSHL labs > Lowe lab
Depositing User: Matt Covey
Date: 15 August 2008
Date Deposited: 22 Feb 2013 19:25
Last Modified: 03 Nov 2017 20:17
PMCID: PMC2518821
Related URLs:
URI: https://repository.cshl.edu/id/eprint/27636

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving